Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹5,592 Cr
verified against source
Revenue YoY
13%
reported change
EBITDA
₹770 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Apollo Hospitals delivered a strong Q4 FY25 with consolidated revenue of INR 5,592 crore (+13% YoY) and PAT of INR 390 crore (+54% YoY). Healthcare services revenue grew 10% to INR 2,822 crore, impacted by ~2% from Bangladesh patient flow disruptions. Occupancy was 67% (metro 70%), ARPOB rose 7% to INR 63,569. Apollo HealthCo revenue grew 17% to INR 2,376 crore, with digital losses narrowing to INR 80 crore (vs INR 111 crore last year). AHLL EBITDA grew 32% to INR 47 crore. Management guided for low-to-mid teens organic hospital growth in FY26, with new bed additions (4,300 beds over 3-4 years) starting to contribute meaningfully from FY27. The digital business targets cash break-even between Q3-Q4 FY26. Key risks include continued Bangladesh headwinds in Q1 FY26 and margin dilution from new hospital ramp-ups.
Colored figures show movement against the previous available record.
Guidance to track
- Management expects organic revenue growth of low-to-mid teens for healthcare services in FY26, with new hospitals contributing from FY27.
- Apollo 24/7 is on track to achieve cash break-even between Q3 and Q4 of FY26, driven by cost reduction and revenue growth.
- Apollo HealthCo (including Keimed) targets revenue of INR 24,000 crore in FY27, with exit run rate crossing INR 25,000 crore.
- Blended EBITDA margin for HealthCo (including Keimed) is expected to exceed 7% by FY27, driven by digital break-even and margin expansion.
Risks flagged
- Continued impact from reduced Bangladesh patient inflows, expected to persist through Q1 FY26, affecting hospital revenue and margins.
- New hospitals in Gurgaon, Pune, Kolkata, and Hyderabad will incur initial losses, potentially compressing healthcare services margins by ~140 bps in FY26.
- Rapid delivery platforms (10-minute) are gaining share in OTC/FMCG, though Apollo's 19-minute proposition and RX focus mitigate impact.
- The Keimed merger process is expected to take 15 months; integration challenges could delay synergy realization.
Key quotes
- We crossed INR 20,000 crore in consolidated revenue and came in at INR 21,794 crore. Alongside, healthcare services revenue crossed the milestone of INR 10,000 crore and came in at INR 11,147 crore.
- We are on track to operationalize our previously announced facilities in Gurgaon, Pune, Kolkata, and Hyderabad later this fiscal year.
- Our trajectory to continuously reduce costs at the same time increase our net revenue on the pharmacy business, which effectively drives the turnaround, is on course.
Research modules